Lv2
140 积分 2023-02-23 加入
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
1个月前
已完结
Circulating tumor DNA in urothelial cancer as an intermediate disease state between localized and advanced stages: Moving from risk factors to micrometastatic disease in the perioperative setting
1个月前
已关闭
Multidisciplinary expert consensus on diagnosis and treatment of multiple lung cancers
1个月前
已完结
结直肠癌KRAS、NRAS和BRAF基因罕见突变类型及其临床意义(附1 513例)
3个月前
已关闭
Aristolochic acid as a probable human cancer hazard in herbal remedies: a review
4个月前
已完结
Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool
4个月前
已完结
ERBB2 Pathway in Biliary Tract Carcinoma: Clinical Implications of a Targetable Pathway
4个月前
已完结
Fluzoparib plus abiraterone versus placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer: a randomized, double-blind, phase 3 trial
6个月前
已完结
The Diagnostic and Prognostic Performance of Urinary FGFR3 Mutation Analysis in Bladder Cancer Surveillance: A Prospective Multicenter Study
8个月前
已完结
皖公网安备34019202002308
